738 Spurious Drugs Cases, 528 Put On Back Burner

Jaipur: The previous Congress government was apparently very kind to the traders selling death in name of medicine. The situation was such that during these five years, Dept. to control spurious medicines found 738 medicines to be of substandard grade in sample testing, but legal action was taken and challan presented only in 90 cases.

Laxity was shown in taking action against firms related to 89 medicines which were directly found to be fake in sample test. Of these, investigation of 64 medicines has not been completed till now while complaints filed only in 25 out of 89 cases.

The slow pace of probe during Cong govt points towards a nexus between govt machinery and pharma firms. In previous govt, responsibility of Drugscontrol Dept. was first with Raghu Sharma and later with Parsadilal Meena. However, pace of probe in these cases remained the same.

Related Posts

  • Pharma
  • June 27, 2025
  • 127 views
Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners,…

  • Pharma
  • June 27, 2025
  • 113 views
Sun Pharma ropes in Richard Ascroft as North America CEO

Mumbai: Sun Pharma has announced the appointment of Richard Ascroft as the new North America (NAM) Chief Executive Officer (CEO). In a statement shared via LinkedIn, the company said, “We…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

MedTech Zone AMTZ Puts Vizag on the Science Map of India

MedTech Zone AMTZ Puts Vizag on the Science Map of India

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Sun Pharma ropes in Richard Ascroft as North America CEO

Sun Pharma ropes in Richard Ascroft as North America CEO

Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen

Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen